Portal de investigação
The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- Bousquet, J
- Jutel, M
- Pfaar, O
- Agache, I
- Czarlewski, W
- Bachert, C
- Bergmann, KC
- Cruz, AA
- Klimek, L
- Kvedariene, V
- Larenas Linnemann, DE
- Papadopoulos, NG
- Patella, V
- Regateiro, FS
- Scichilone, N
- Shamji, MH
- Sheikh, A
- Valovirta, E
- Ventura, MT
- Zuberbier, T
Unidades de investigação
Abstract
Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many international or national practice guidelines have been produced, but the evidence-based method varies and they do not usually propose care pathways. The present article considers the possible role of mobile health in AIT for allergic rhinitis/asthma. There are no currently available validated biologic biomarkers that can predict AIT success, and mobile health biomarkers have some relevance. In the current article, the following aspects will be discussed: patient stratification for AIT, symptom-medication scores for the follow-up of patients, clinical trials, as well as the approach of the European Academy of Allergy and Clinical Immunology. (C) 2021 American Academy of Allergy, Asthma & Immunology
Copyright © 2021 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Dados da publicação
- ISSN/ISSNe:
- 2213-2198, 2213-2201
- Tipo:
- Review
- Páginas:
- 1805-1812
- PubMed:
- 33662672
- Link para outro recurso:
- www.scopus.com
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE Elsevier
Citações Recebidas na Web of Science: 13
Citações Recebidas na Scopus: 14
Documentos
- Não há documentos
Filiações
Keywords
- mHealth; ARIA; EAACI; Allergic rhinitis; Immunotherapy
Projetos associados
Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal (EPI-ASTHMA) - NCT05169619
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (EPI-ASTHMA) . AstraZeneca . 2021
Utilização em estudos observacionais do Registo de Asma Grave Portugal.
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Observacional Académico (RAG) . 2020
Use of secondary data, health technology assessment methods and economic modelling applied to penicillin allergy
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Using different data sources for the identification of asthma patients and those at high risk of adverse outcomes
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Phenotypes of Chronic Diseases of the Airways: Towards Multidimensional Data -Driven Profiling
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
